Clinical trials: Brain Stroke
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC
Patent Foramen Ovale, Cryptogenic Stroke
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
To evaluate the performance of Cera™ patent foramen ovale occluders developed by Lifetech Scientific (Shenzhen) Co., LTD;
- Trial name
- NCT05774288
- Testing
- Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders
- Where
- 14 sites in China
- Volunteers
- 244 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
A study to Evaluate the Efficacy and Safety of Renexin CR in patients with Acute Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05445895
- Testing
- Renexin CR 200/160mg, Plavix 75mg
- Where
- South Korea
- Volunteers
- 483 people
- Sponsor
- SK Chemicals Co., Ltd.
Stroke
Neurorehabilitation of the Hand
Stroke is the number one cause of adult disability in the world. Due to the neurological damage from stroke, a vast majority of individuals suffer from hand function disability (~70%).
- Trial name
- NCT05549375
- Testing
- MyHand System Hand Rehabilitation
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- IRegained Inc.
Secondary Stroke
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications.
- Trial name
- ROXI-DAISEN (NCT07876492)
- Testing
- Cenvacibart
- Volunteers
- 6,106 people
- Sponsor
- Regeneron Pharmaceuticals
Stroke, Ischemic
A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ⅱb/Ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets, a novel oral neuroprotective agent, and explore the…
- Trial name
- XY03-EA (NCT06755944)
- Testing
- XY03-EA 150 mg (per dose), XY03-EA 300 mg (Regimen A), XY03-EA 300 mg (Regimen B)
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Ischemic Stroke, Acute
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus…
- Trial name
- FRIDA-CT (NCT07324837)
- Testing
- non-immunogenic staphylokinase
- Where
- 17 sites in Russia
- Volunteers
- 990 people
- Sponsor
- Supergene, LLC
Acute Ischemic Stroke
Efficacy and Safety Evaluation of the Thromboaspiration Catheter System iNstroke in Patients With Acute Ischemic Stroke
First prospective, single-arm, single-centre study to evaluate the efficacy and safety of the iNstroke thromboaspiration catheter system (iNstroke) for stroke in patients with acute ischemic stroke.
- Trial name
- ASPiC (NCT05720975)
- Testing
- iNstroke
- Where
- Spain
- Volunteers
- 113 people
- Sponsor
- iVascular S.L.U.
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Stroke
Study of ONO-2506 in Patients With Acute Ischemic Stroke
The purpose of this study is to determine the efficacy and safety of ONO-2506 compared to placebo in patients with acute ischemic stroke.
- Trial name
- NCT00229177
- Testing
- ONO-2506
- Where
- 9 sites in Japan
- Volunteers
- 757 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Ischemic Stroke
Phase 2 Study of TXA127 in Post-ischemic Stroke Patients
This is a 50-patient, Phase 2, double-blind, randomized, placebo-controlled, hybrid decentralized study to evaluate the safety and efficacy of daily subcutaneous (SC) injection of TXA127 in post-ischemic stroke patients.
- Trial name
- NCT06135103
- Testing
- talfirastide
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Constant Therapeutics LLC
Stroke, Ischemic
SYNCHRONISE: LVO Triage Timing and Outcome Study
The objective of this study is to evaluate the impact of Viz LVO in hospital systems with non-interventional and interventional (spoke and hub) stroke centers on the timing and outcomes of patients with suspected acute ischemic…
- Trial name
- NCT04608617
- Testing
- Viz LVO (De Novo Number DEN170073), Baseline Effectiveness Cohort
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- Viz.ai, Inc.
Stroke, Cerebral Ischemia
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00300196
- Testing
- Ancrod (Viprinex)
- Where
- 94 sites in United States, Australia and 9 more
- Volunteers
- 311 people
- Sponsor
- Neurobiological Technologies
Non-valvular Atrial Fibrillation (NVAF)
AMPLATZER™ Cardiac Plug Observational Post-Approval Study
The purpose of this study is to observe the safety and effectiveness of the AMPLATZER™ Cardiac Plug (ACP) device in Chinese population indicated for use of AMPLATZER™ Cardiac Plug after its market approval by China FDA (CFDA).
- Trial name
- ACP China (NCT02954237)
- Testing
- AMPLATZER™ Cardiac Plug
- Where
- 6 sites in China
- Volunteers
- 91 people
- Sponsor
- Abbott Medical Devices
PFO, Stroke
PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness
The primary object of this study is to demonstrate the continued safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or…
- Conditions
- PFO, Stroke, Transient Ischemic Attack, Migraine
- Trial name
- Paradigm IV (NCT00529945)
- Testing
- PFx Closure System
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cierra
Acute Ischemic Stroke
Prospective, Multicentre Study to Evaluate the Thrombectomy System for Stroke: iNedit, iNdeep and iNtercept
First prospective, single-arm, multicentre study to evaluate the safety and efficacy of the overall stroke thrombectomy system: iNedit, iNdeep and iNtercept in patients with acute ischemic stroke.
- Trial name
- SEMTiC (NCT05893719)
- Testing
- iNedit, iNdeep, iNtercept
- Where
- 18 sites in Belgium, Germany and 1 more
- Volunteers
- 175 people
- Sponsor
- iVascular S.L.U.
Acute Ischemic Stroke
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
The purpose of this trial is to determine if intravenous administration of the metal ion trapping agent DP-b99 up to 9 hours following acute ischemic stroke onset, and then for 3 additional days (4 consecutive days in total) is…
- Trial name
- MACSI (NCT00893867)
- Testing
- DP-b99
- Where
- 154 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- D-Pharm Ltd.
Acute Ischemic Stroke
A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92 Medical MonoPoint® Reperfusion System with the Hi Point 88 and HiPoint 70…
- Trial name
- NCT05018650
- Testing
- Route 92 Medical Reperfusion System
- Where
- 30 sites in United States, New Zealand
- Volunteers
- 250 people
- Sponsor
- Route 92 Medical, Inc.
Stroke, Secondary Prevention
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months.
- Trial name
- NCT02239120
- Testing
- optional ASA as comedication, ASA 100 mg
- Where
- 569 sites in United States, Argentina and 40 more
- Volunteers
- 5,390 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Stent Retriever's(TonbridgeMT) Endovascular Therapy for Acute Ischemic Stroke(AIS)
The study is a prospective, multi-center, stratified randomized, single-blind, parallel assignment, active control, non-inferiority trial.
- Trial name
- NCT03210623
- Testing
- stent retriever(TonbridgeMT), Solitaire™
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Ton-Bridge Medical Tech. Co., Ltd